Participants 60 years of age or older at enrolment.
Healthy participants, or participants with stable long-term medical conditions, if the investigator decides they can take part.
Adults who can walk and live in the community or in assisted-living/long-term care settings with minimal help.
Participants who can give signed informed consent and follow study visits and procedures, including the 7-day electronic diary and blood tests.
You may not be if
Confirmed RSV infection 180 days or less before study vaccination.
Any past history of Guillain-Barré syndrome.
Severe reaction to a vaccine or severe allergy to a study vaccine component or related vaccine.
Serious or unstable medical condition that the investigator believes makes the study unsafe.
Immunocompromised status, based on medical history and/or examination.
Previous receipt of any licensed or investigational RSV vaccine or RSV preventive monoclonal antibody, or planned receipt during the study.
Please refer to the study contact for further eligibility details Contacts/Locations Central Contact Person: Pfizer CT.gov Call Center Telephone: 1-800-718-1021 Email: ClinicalTrials.gov\[email protected]
